DURAGESIC-50
LOE ApproachingNDATRANSDERMALFILM, EXTENDED RELEASE
Approved
Aug 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 4d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DURAGESIC-50 is a transdermal extended-release film formulation approved in 1990 for chronic pain management. The product delivers active pharmaceutical through a skin patch system, providing sustained therapeutic exposure. Specific indication details are not available in current data.
LOE Approaching
As LOE approaches, the brand team is likely focused on defending market share and optimizing operational efficiency rather than growth investments.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
A Study to Assess the Bioequivalence of 2 Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) (150 mg/850 mg) With Respect to the Individual Components of Canagliflozin (1 x 300 mg) and Metformin IR Tablets (2 x 850 mg) in Healthy Volunteers
Started Sep 2011
64 enrolled
Healthy
Career Relevance
Roles on DURAGESIC-50 focus on defending a mature product and managing the transition to generic competition. Career growth is limited; opportunities lie in optimizing operational efficiency, compliance, and stakeholder management during LOE.
Brand Manager
Worked on DURAGESIC-50 at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.